NCT05805956

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

An Open-label, Multicenter, First-in-human Dose-escalation and Cohort Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMM2902 in the Treatment of HER2-expressing Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 105 (estimated)
• Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial is an open-label, multicenter, first-in-human dose-escalation and cohort expansion Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of IMM2902 in the treatment of HER2-expressing advanced solid tumors

Conditions

• Advanced Solid Tumor
• Advanced Lung Cancer
• Advanced Gastric Carcinoma
• Advanced Cholangiocarcinoma

Interventions

Type	Name	Description
DRUG	IMM2902	a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47

Timeline

• Start date: 2022-02-15
• Primary completion: 2024-10-01
• Completion: 2024-10-01
• First posted: 2023-04-10
• Last updated: 2023-04-10

Locations

2 sites across 1 country: China

Regulatory

• FDA-regulated drug study